Who owns CTMX?
Institutional ownership of CytomX Therapeutics Inc. from Form 13F, Q2 2026
179 institutional managers reported holding CytomX Therapeutics Inc. (CTMX) in Form 13F filings for Q2 2026, with 213,413,474 shares worth $800M. The largest reported holder was FMR LLC. Managers that filed both quarters added a net 19,585,299 shares (+10.1%). 45 opened new positions and 45 sold out.
- Funds holding
- 179
- Value held
- $800M
- New / sold out
- 45 / 45
- Net shares, same filers
- +10.1%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of CTMX
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| FMR LLC | $123M | 15.3% | 32,714,937 | Added |
| Kynam Capital Management, LP | $81.4M | 10.2% | 21,703,093 | Added |
| BlackRock, Inc. | $65.8M | 8.2% | 17,559,822 | Added |
| Bank of America Corp | $56.6M | 7.1% | 15,082,617 | Added |
| State Street Corp | $44.1M | 5.5% | 11,747,236 | Added |
| Perceptive Advisors LLC | $39.1M | 4.9% | 10,439,185 | Added |
| Vanguard Capital Management LLC | $32.0M | 4.0% | 8,525,457 | Trimmed |
| Point72 Asset Management, L.P. | $29.3M | 3.7% | 7,811,033 | Trimmed |
| Wellington Management Group LLP | $19.4M | 2.4% | 5,168,961 | Added |
| Venrock Adviser, LLC | $18.7M | 2.3% | 4,982,124 | Trimmed |
| Baker Bros. Advisors LP | $18.7M | 2.3% | 4,975,826 | Unchanged |
| Geode Capital Management, LLC | $17.5M | 2.2% | 4,678,716 | Added |
| Elmind Capital, LP | $17.1M | 2.1% | 4,550,000 | Unchanged |
| Nextech Invest Ltd. | $16.7M | 2.1% | 4,449,932 | Unchanged |
| Two Sigma Investments, LP | $15.5M | 1.9% | 4,132,643 | Added |
| Eversept Partners, LP | $13.3M | 1.7% | 3,558,497 | Added |
| UBS Group AG | $13.0M | 1.6% | 3,468,359 | Added |
| Siren, L.L.C. | $13.0M | 1.6% | 3,457,711 | Unchanged |
| ADAR1 Capital Management, LLC | $12.6M | 1.6% | 3,365,118 | Trimmed |
| Citadel Advisors LLC | $11.7M | 1.5% | 3,110,509 | Trimmed |
| Marshall Wace, LLP | $11.3M | 1.4% | 3,024,351 | Trimmed |
| Woodline Partners LP | $7.7M | 1.0% | 2,040,210 | Added |
| Goldman Sachs Group Inc | $7.5M | 0.9% | 2,003,652 | Added |
| Dimensional Fund Advisors LP | $7.0M | 0.9% | 1,860,290 | Trimmed |
| Qube Research & Technologies Ltd | $6.8M | 0.9% | 1,824,564 | Trimmed |
Share of 13F holdings is each fund's shares as a share of the 213,413,474 CTMX shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- BlackRock, Inc. Added+$46.2M
- Kynam Capital Management, LP Added+$25.1M
- State Street Corp Added+$22.8M
- Bank of America Corp Added+$18.3M
- Geode Capital Management, LLC Added+$9.8M
- Wellington Management Group LLP Added+$5.9M
- Two Sigma Investments, LP Added+$5.3M
- Tudor Investment Corp Et Al New+$5.2M
- Northern Trust Corp Added+$4.0M
- Vanguard Portfolio Management LLC Added+$3.6M
Biggest sellers in Q2 2026
- Venrock Adviser, LLC Trimmed-$18.8M
- Jefferies Financial Group Inc. Sold out-$14.4M
- Citadel Advisors LLC Trimmed-$8.6M
- Millennium Management LLC Trimmed-$7.4M
- Susquehanna International Group, LLP Trimmed-$6.7M
- Patient Square Capital LP Sold out-$5.1M
- Jane Street Group, LLC Sold out-$4.7M
- Eventide Asset Management, LLC Sold out-$4.2M
- Trexquant Investment LP Sold out-$4.2M
- Marshall Wace, LLP Trimmed-$4.2M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $183M and sold $121M; 72 added and 33 trimmed.
Schedule 13D and 13G filings on CTMX
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-10STATE STREET CORP SCHEDULE 13G filed by CytomX Therapeutics Inc.Schedule 13G
- 2026-08-07STATE STREET CORP SCHEDULE 13G filed by CytomX Therapeutics Inc.Schedule 13G
- 2026-08-03BANK OF AMERICA CORP /DE/ SCHEDULE 13G filed by CytomX Therapeutics Inc.Schedule 13G
- 2026-07-27BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
- 2026-03-04Kynam Capital Management, LP SCHEDULE 13G filed by CytomX Therapeutics Inc.Schedule 13G
- 2025-08-21PERCEPTIVE ADVISORS LLC SCHEDULE 13G filed by CytomX Therapeutics Inc.Schedule 13G
- 2025-08-14ORBIMED ADVISORS LLC SCHEDULE 13G filed by CytomX Therapeutics Inc.Schedule 13G
- 2025-08-06FMR LLC SCHEDULE 13G filed by CytomX Therapeutics Inc.Schedule 13G
Questions about CTMX ownership
- Who owns CTMX stock?
- 179 institutional investment managers reported CTMX positions in their Form 13F filings for Q2 2026, holding 213,413,474 shares worth $800M in total. FMR LLC reported the largest position.
- Are funds buying or selling CTMX?
- In Q2 2026, 45 managers opened new CTMX positions, 72 added, 33 trimmed and 45 sold out. Managers that filed in both quarters added a net 19,585,299 shares.
- How current is this CTMX institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to CTMX by CUSIP. Options are left out. CTMX news and filings · CTMX insider trades · Top funds